Clinical efficacy, immunogenicity and safety of RTS,S/AS01, R21/Matrix-M and candidate malaria vaccines in children: A systematic review and meta-analysis.
Sep 2026· Journal of Infection and Public Health· Vol 19 10, pp.
103356
· 0 citations· 58 references
Medicine
TL;DR
RTS,S and R21 vaccines achieve the highest efficacy particularly in combination with SMC and should be integrated into childhood malaria control strategies emphasizing the need for booster strategies and long-term effectiveness monitoring in endemic settings.
Abstract
Background
Malaria remains a global public health emergency with high mortality especially among children under 5 years. Despite increased research on pediatric malaria vaccines, comprehensive evidence syntheses are limited. We aimed to assess the efficacy and safety of currently available malaria vaccines in children.
Methods
Following PRISMA we included Phase IIb-IV and post-marketing studies from PubMed, SCOPUS, WoS, ClinicalTrials.gov, ISRCTN, EUCTR, CTIS and PACTR. Licensed and candidate vaccines used to individuals < 18 years were compared with controls or seasonal malaria chemoprevention (SMC). Outcomes were seroconversion, incidence of clinical malaria and serious adverse events (SAE). Meta-analyses were performed for the intention-to-treat cohorts with subgroup analyses by vaccine type and follow-up (PROSPERO: CRD420251032609).
Results
56 trials were included (134424 participants). The proportional meta-analysis revealed an overall SAE rate of 16% (95% CI 12% -19%), higher for RTS,S/AS02 (29%; 95% CI 14%-44%) and lower for R21-MM (3%; 95% CI 2%-3%). In comparative analyses vaccination reduced SAE risk by 9% vs controls (RR=0·91; 95% CI 0·86-0·96). Overall vaccine efficacy (VE) was 31% (IRR=0·69; 95% CI 0.57-0.84), higher for RTS,S/AS02 (47%; IRR=0·53; 95% CI 0.36-0.80) and RTS,S/AS01 (32%; IRR=0·68; 95% CI 0.57-0.81). R21-MM showed a VE of 72% (IRR=0·28; 95% CI 0.22-0.34, single trial Phase 2b). Efficacy declined with time: 33% (IRR=0·67; 95% CI 0.43-1.02) within 12 months, 35% (IRR=0·65; 95% CI 0.50-0.82) at 12-36 and 11% (IRR=0·89; 95% CI 0.81-0.99) beyond 36 months. The combination of vaccination and SMC showed 65% (IRR=0·35; 95% CI 0.23-0-51) efficacy. Cumulative seroconversion rate was 0·99 (95% CI 0·98-1·00). Comparative seroconversion analysis was not feasible due to absent control data. No study was rated as low quality by RoB2.
Conclusions
Malaria vaccines in children show a favorable safety profile and provide meaningful although time-limited protection against clinical malaria. RTS,S and R21 vaccines achieve the highest efficacy particularly in combination with SMC. Malaria vaccination should be integrated into childhood malaria control strategies emphasizing the need for booster strategies and long-term effectiveness monitoring in endemic settings.
Background/Objectives: The efficacy and safety profiles of CYD-TDV and TAK-003 are established, but multiple publications may derive from the same randomized trial population and therefore not represent independent evidence. We evaluated efficacy, immunogenicity, and safety while distinguishing independent trials from...
J. P. Sanchez Guanilo, Carmen A. Contreras, M. Arce-Huamaní· Vaccines· 0 citations
ABSTRACT Individual studies indicate stronger and persistent long-term immunogenicity with TZ84-based than HM175-based hepatitis A vaccines. This systematic review and meta-analysis compared immunogenicity and safety of inactivated TZ84- and HM175-based hepatitis A vaccines in children and adolescents. Studies involvin...
R. Kundu, A. Ghosh, A. Toppo et al.· Human Vaccines & Immunothera...· 0 citations
Across the broader evidence base, the R21/Matrix-M vaccine was generally well tolerated and elicited strong anti-CSP/anti-NANP antibody responses, and the central efficacy estimate is robust to alternative analytic specifications.
Aneeq Ur Rehman, V. Nnaemeka, Muhammad Hassan Nasir et al.· Vaccines· 0 citations
Abstract Background Tuberculosis (TB) remains a leading cause of morbidity and mortality among people living with HIV (PLHIV). Although M72/AS01 demonstrated efficacy against active TB in HIV-negative adults, its safety in PLHIV is uncertain. As AS01 induces strong innate immune activation, evaluating tolerability in i...
Pedro Sandes Pereira, Judson C. S. Neri, Deivide Oliveira-de-Souza et al.· Open Forum Infectious Diseas...· 0 citations
Background Global oral cholera vaccine (OCV) supply shortages and the retirement of Shanchol necessitate absolute reliance on alternative formulations. We conducted a systematic review and meta-analysis to evaluate the immunogenicity and safety of Euvichol variants compared with the historical Shanchol benchmark. Metho...
K. M. Al-Dhayani, Zaid Hasan, Khaled Ben Alwaleed Hassan Alastah et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.